Tissue specific epigenetic silencing of the distinct tumor suppressor genes in lung cancer

Scientific Research and Essays

Volumn 5, Issue 9, 2010, Pages 849-855

  Arslan, Sulhattin ^a   Karadayi, Sule ^a   Ozdemir, Ozturk ^a   Sahin, Ekber ^a   Ozdemir, Semra ^b   Akkurt, Ibrahim ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Numune Hospital   (Turkey)

Author keywords

Epigenetic alterations; Lung carcinoma; Tumor suppressor genes

Indexed keywords

EID: 77953571308     PISSN: None     EISSN: 19922248     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Arslan S, Dogan T, Koksal B, Yildirim ME, Gumus C, Elagoz S (2008). Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with non-small cell lung carcinoma: A case report. Lung India 25: 148-151.
2. Belinsky SA (1998). Role of the cytosine DNA-methyltransferase and p16INK4a genes in the development of mouse lung tumors. Exp. Lung Res. 24(4): 463-79.
3. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G (2005). CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur. J. Cancer 41(8): 1223-1236.
4. Demoly P, Pujol JL, Godard P, Michel FB (1994). Oncogenes and antioncogenes in lung cancer. Presse Med. 23(6): 291-7.
5. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999). Inactivation of the DNA repair gene O6 methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59(4): 793-797.
6. Esteller M, Herman JG (2002). Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J. Pathol. 196(1): 1-7.
7. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H, Tanimoto M (2005). Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11(3): 1219-1225.
8. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 4525-30.
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006). Cancer statistics. CA Cancer J. Clin. 56(2): 106-130.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007). Cancer statistics. CA Cancer J. Clin. 57(1): 43-66.
11. Kuo JC, Wang WJ, Yao CC, Wu PR, Chen RH (2006). The tumor suppressor DAPK inhibits cell motility by blocking the integrinmediated polarity pathway. J. Cell Biol. 172(4): 619-631.
12. Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y (2007). Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 26(32): 4699-4713.
13. Ozdemir O, Bulut HE, Korkmaz M, Onarlioglu B, Colak A (2000). Increased cell proliferation and RMsp1 fragmentation induced by 5- aza-2'-deoxycytidine in rat testes related to the gene imprinting mechanism. Exp. Toxic Pathol. 52(4): 317-322.
14. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003). A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63: 1114-1121.
15. Porebska I, Kosacka M, Wyrodek E, Jankowska R (2009). Expression of p53, bcl-2 and nm23 proteins in squamous cell lung cancer. Pneumonol. Alergol. Pol. 77(2): 131-137.
16. Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW (2007). SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int. J. Cancer. 121(5): 1028-1035.
17. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T (2008). Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br. J. Cancer. 25, 98(6): 1147-1156.
18. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP (2009). CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 19(3): 146-155.
19. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M, Dahiya R (2006). Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin. Cancer Res. 12(23): 6989-6997.
20. Wang X, Wang M, MacLennan GT, Abdul-Karim FW, Eble JN, Jones TD, Olobatuyi F, Eisenberg R, Cummings OW, Zhang S, Lopez-Beltran A, Montironi R, Zheng S, Lin H, Davidson DD, Cheng L (2009). Evidence for common clonal origin of multifocal lung cancers. J. Natl. Cancer Inst. 101(8): 541-3.
21. Yamada N, Nishida Y, Tsutsumida H, Goto M, Higashi M, Nomoto M, Yonezawa S (2009). Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. British J. Cancer 100(2): 344-351.
22. Zaridze DG (2004). Epidemiology and etiology of malignant tumors. In: Zaridze DG. Ed. Kantserogenez. Moscow: Meditsina. pp. 29-85.
23. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001). Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61(1): 249-255.